* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Thursday, June 12, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

    The Analyst Verdict: PENN Entertainment In The Eyes Of 7 Experts – Nasdaq

    7 Experts Reveal the Ultimate Verdict on PENN Entertainment

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    Leading Proxy Advisory Firm Glass Lewis Recommends Shareholders Vote “FOR” Both of PENN Entertainment’s Director Nominees on the WHITE Proxy Card – Business Wire

    Glass Lewis Urges Shareholders to Support All PENN Entertainment Director Nominees on the WHITE Proxy Card

    Cisco Partners with Monumental Sports & Entertainment to Power New D.C. Arena – Cisco Newsroom

    Cisco Teams Up with Monumental Sports & Entertainment to Revolutionize the New D.C. Arena Experience

    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    MSI Viking and Mahr Host Technology Day – WSPA 7NEWS

    Step Inside the Thrilling World of MSI Viking and Mahr Technology Day!

    6.12pm is the new 8pm – Go Technology – cgastrategy.com

    6.12pm is the new 8pm – Go Technology – cgastrategy.com

    Russian Scientists Develop Sub-Ångström Technology for Next-Gen Quantum Processors – The Quantum Insider

    Russian Scientists Pioneer Sub-Ångström Technology to Revolutionize Next-Gen Quantum Processors

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    SunHydrogen Unveils Large Hydrogen Reactor in Houston – Fuel Cells Works

    SunHydrogen Launches Groundbreaking Large-Scale Hydrogen Reactor in Houston

    Technology, Labor Rights, and Political Power in Kenya and Across Africa – Tech Policy Press

    How Technology is Shaping Labor Rights and Political Power Across Africa

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

    The Analyst Verdict: PENN Entertainment In The Eyes Of 7 Experts – Nasdaq

    7 Experts Reveal the Ultimate Verdict on PENN Entertainment

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    Leading Proxy Advisory Firm Glass Lewis Recommends Shareholders Vote “FOR” Both of PENN Entertainment’s Director Nominees on the WHITE Proxy Card – Business Wire

    Glass Lewis Urges Shareholders to Support All PENN Entertainment Director Nominees on the WHITE Proxy Card

    Cisco Partners with Monumental Sports & Entertainment to Power New D.C. Arena – Cisco Newsroom

    Cisco Teams Up with Monumental Sports & Entertainment to Revolutionize the New D.C. Arena Experience

    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    MSI Viking and Mahr Host Technology Day – WSPA 7NEWS

    Step Inside the Thrilling World of MSI Viking and Mahr Technology Day!

    6.12pm is the new 8pm – Go Technology – cgastrategy.com

    6.12pm is the new 8pm – Go Technology – cgastrategy.com

    Russian Scientists Develop Sub-Ångström Technology for Next-Gen Quantum Processors – The Quantum Insider

    Russian Scientists Pioneer Sub-Ångström Technology to Revolutionize Next-Gen Quantum Processors

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    SunHydrogen Unveils Large Hydrogen Reactor in Houston – Fuel Cells Works

    SunHydrogen Launches Groundbreaking Large-Scale Hydrogen Reactor in Houston

    Technology, Labor Rights, and Political Power in Kenya and Across Africa – Tech Policy Press

    How Technology is Shaping Labor Rights and Political Power Across Africa

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Can a GLP-1 Agonist Improve Parkinson’s Symptoms?

December 20, 2023
in Health
Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
Share on FacebookShare on Twitter

An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed.

Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III scores at 36 weeks, according to Andrew McGarry, MD, of Rowan University in Camden, New Jersey, and colleagues.

Compared with placebo, the difference at 36 weeks was -0.39 (95% CI -2.96 to 2.18, P=0.77) for 2.5 mg and 0.6 (-2.28 to 3.00, P=0.79) for 5.0 mg, McGarry and co-authors reported in Lancet Neurology.

However, a subgroup analysis suggested the possibility of motor benefit in participants under age 60, the researchers said.

The GLP-1 receptor is present in the brain, and agonist activity is thought to be anti-inflammatory by reducing microglia activation. Exenatide is a GLP-1 receptor agonist approved to treat type 2 diabetes.

“In a database of more than 100,000 individuals with diabetes, those using GLP-1 receptor agonists had a 62% lower risk of developing Parkinson’s disease,” McGarry and colleagues pointed out. In 2017, a single-center trial showed that exenatide had positive effects on Parkinson’s motor scores that continued beyond the period of exposure.

People with type 2 diabetes have an increased risk of Parkinson’s disease, particularly those with early diabetes onset (ages 25-44) and a low BMI (below 18.5), noted Claudia Trenkwalder, MD, and Brit Mollenhauer, MD, of the University Medical Center Göttingen in Germany, in an accompanying editorial.

“The Parkinson’s disease course can be faster and more severe for individuals with type 2 diabetes than for those without type 2 diabetes, and it can be characterized by motor fluctuations in response to treatment occurring earlier and a more rapid decline in cognitive function,” Trenkwalder and Mollenhauer wrote.

Trials like the NLY01 phase II study that investigate the preventive potential of existing drugs are urgently needed, the editorialists observed.

“One strategy to move forward with GLP-1 agonists could be to better select the participants with Parkinson’s disease — e.g., young people with high inflammatory activity who would benefit most from the targeted metabolic and inflammatory mechanism of GLP-1 agonism,” they suggested.

“In addition to carefully selecting participants at an appropriate disease stage, improvements to the design of studies in people with established Parkinson’s disease need to be pursued,” they added.

McGarry and co-authors randomized 255 people with early untreated Parkinson’s disease to subcutaneous 2.5 mg or 5.0 mg NLY01, or placebo (85 people in each group). Participants were told to administer the drug or placebo once a week for 36 weeks. Mean age was 61.5 and more than half of participants were men.

The primary efficacy endpoint was change from baseline to week 36 in the sum of MDS-UPDRS parts II and III scores. Part II assesses motor aspects of experiences of daily living and part III is a motor examination. Each MDS-UPDRS subscale has a rating from 0 (normal) to 4 (severe).

Secondary endpoints included MDS-UPDRS part I scores (non-motor aspects of experiences of daily living), clinical and patient impressions of severity, cognitive test scores, and dopamine transporter imaging parameters. No secondary endpoint differed from placebo at either dose.

NLY101 was generally safe and well tolerated. Gastrointestinal disorders emerged in 61% of the 2.5-mg dose group and 75% of the 5.0-mg group, most frequently nausea.

Participants under age 60 showed nominally significant reductions from baseline in the sum of MDS-UPDRS parts II and III scores at 36 weeks compared with placebo, “a finding that could be driven in part by a greater decline in the younger placebo group,” McGarry and colleagues acknowledged. “Further studies should look to test a younger population for potentially better treatment outcomes.”

The phase II trial may have been too short to see effects clearly, the researchers noted. Exenatide-PD3, a phase III, 2-year study of exenatide in 200 people with mild-to-moderate Parkinson’s disease on standard treatment, is underway; results are expected in 2024.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

Funding for the study came from D&D Pharmatech-Neuraly.

McGarry and several co-authors received salary support from Neuraly for their work on the study. Other co-authors were either Neuraly employees, employees of the contract research organization, or received research support from Neuraly. One co-author received stock and equity in D&D Pharmatech.

Editorialists reported relationships with General Electric Healthcare, Bial, Roche, Biogen, AbbVie, Amprion, the Michael J. Fox Foundation for Parkinson’s Research, Aligning Science Across Parkinson’s, AbbVie, Boehringer, Britannia, Ono, Convatec, UCB, Alexion, EU Horizon 2020, ERA-NET BRAVA, and the International Parkinson and Movement Disorder Society.

Primary Source

Lancet Neurology

Source Reference: McGarry A, et al “Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomized, double-blind, placebo-controlled trial” Lancet Neurol 2024; DOI: 10.1016/S1474-4422(23)00378-2.

Secondary Source

Lancet Neurology

Source Reference: Trenkwalder C and Mollenhauer B “The long road to neuroprotection for Parkinson’s disease” Lancet Neurol 2024; DOI: 10.1016/S1474-4422(23)00462-3.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/neurology/parkinsonsdisease/107945

Tags: Agonisthealthimprove
Previous Post

Explanations Don’t Help Clinicians Spot Biased AI

Next Post

Clinical Challenges: Managing Pediatric Crohn’s Disease

Colville Tribes and Ecology Join Forces to Boost Air Quality in Washington State

June 12, 2025
New menstrual pad device tracks period blood for signs of disease – Live Science

New menstrual pad device tracks period blood for signs of disease – Live Science

June 12, 2025
Can anything save US science from Donald Trump? – Times Higher Education

Is There Hope for US Science Under Donald Trump?

June 12, 2025
Philly VegFest brings all-things vegan to the community – The Philadelphia Tribune

Philly VegFest brings all-things vegan to the community – The Philadelphia Tribune

June 12, 2025
Making America Backward Again – Rolling Stone

Making America Backward Again – Rolling Stone

June 12, 2025
Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

How Data Storage and Protection Are Transforming the Media & Entertainment Industry

June 12, 2025
Covenant Health educating the youth on healthcare opportunities – KCBD

Unlocking Thrilling Healthcare Career Paths for Today’s Youth

June 12, 2025
Republicans to Press Hochul, Walz and Pritzker on Immigration in Hearing – The New York Times

Republicans Intensify Pressure on Hochul, Walz, and Pritzker Ahead of Key Immigration Hearing

June 12, 2025
MSI Viking and Mahr Host Technology Day – WSPA 7NEWS

Step Inside the Thrilling World of MSI Viking and Mahr Technology Day!

June 12, 2025
Connections: Sports Edition hints for June 11, 2025, puzzle No. 261 – The New York Times

Connections: Sports Edition hints for June 11, 2025, puzzle No. 261 – The New York Times

June 12, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (682)
  • Economy (697)
  • Entertainment (21,601)
  • General (15,343)
  • Health (9,738)
  • Lifestyle (701)
  • News (22,149)
  • People (698)
  • Politics (704)
  • Science (15,914)
  • Sports (21,198)
  • Technology (15,683)
  • World (680)

Recent News

Colville Tribes and Ecology Join Forces to Boost Air Quality in Washington State

June 12, 2025
New menstrual pad device tracks period blood for signs of disease – Live Science

New menstrual pad device tracks period blood for signs of disease – Live Science

June 12, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version